Clinical trial
A Phase 4 Double-Blind Study to Assess the Safety and Tolerability of Intravenous Administration of GLASSIA in Healthy Adult Volunteers
NCT01651351 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4 Double-Blind Study to Assess the Safety and Tolerability of Intravenous Administration of GLASSIA in Healthy Adult Volunteers
- Lead sponsor
- Baxalta now part of Shire
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 31, 2012
- Completion date
- January 16, 2013
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alpha1-antitrypsin deficiency, healthy volunteers